Starling Oncology Inc.

NASDAQ · STLN
6.53−0.12−1.80%as of Oct 30, 2026

Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients. While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty infusion, oral pharmacy needs, as well as enrolling patients in clinical trials, where appropriate, TOI's true mission lies in our differentiated ability to partner with managed care providers and other risk-bearing entities to transfer the risk and patient coordination responsibility of treating cancer in the subset of the population that is experiencing an oncology treatment episode. To do this, we utilize a combination of gain/loss sharing, capitation, and full delegation contracts at the population-level, which allow TOI to control the treatment of oncology patients in an outpatient setting,

From the 10-K filed Mar 12, 2026

CEO
Dr. Daniel Virnich FACHE, M.B.A., M.D.
Sector
Healthcare
Industry
Medical - Care Facilities
Employees
641
Headquarters
Cerritos, CA
Fiscal year end
December
1 year+1.76 (+36.90%)
STLN+36.90%
$5.00$5.50$6.00$6.50$7.00
$6.53
10MVol
Jul 29Aug 17Sep 3Sep 24Oct 13Oct 30
FundalyzePowered by fundalyze.ai
4.757.13

as of Oct 22, 2026 · today 6.53, 75% of the way from low to high

No dividends on record.

A company that pays none, or whose history has not arrived yet, shows nothing here.

Valuation

Market cap$656.06Mas of Oct 22, 2026
P/E-18.1×TTM · Q3 2025 – Q2 2026
P/S1.1×TTM · Q3 2025 – Q2 2026
P/B-26.3×Q2 2026
Dividend yield—no dividends on record

Results, trailing twelve months

Revenue$587.24MTTM · Q3 2025 – Q2 2026
Net income-$36.29MTTM · Q3 2025 – Q2 2026
Diluted EPS-$0.3TTM · Q3 2025 – Q2 2026
Gross margin15.7%TTM · Q3 2025 – Q2 2026

Balance and cash

Enterprise value$694.84Mas of Oct 22, 2026
Long-term debt$79.87MQ2 2026
Free cash flow-$3.29MTTM · Q3 2025 – Q2 2026
Stock-based comp.$5.10MTTM · Q3 2025 – Q2 2026

Shares and market

Shares outstanding100.47Mas of Oct 23, 2026
Average volume1.23Mshares a day, last 3 months
Beta0.42

Financial statements

Total operating revenue +27.8% $393.41M → $502.73M, year ended Dec 31, 2025

Comps

Valuation, growth and margins against the closest competitors

Filings

10-K filed Mar 12, 2026 · 10-Q Aug 6, 2026

FilingFiled
10-Q for Quarter Ended June 2026Aug 6, 2026
10-Q for Quarter Ended March 2026May 7, 2026
10-K for Fiscal Year Ended December 2025Mar 12, 2026
10-Q for Quarter Ended September 2025Nov 13, 2025

Insiders

$23.51M sold $2.69M bought · open market, 12 months to Aug 21, 2026

InsiderTypeValue
Brad HivelyAug 21, 2026Sale$1.95M ↗
Jorey ChernettAug 14, 2026Purchase$78.48K ↗
Jorey ChernettJul 21, 2026Purchase$94.86K ↗
Yale PodnosJul 14, 2026Sale$34.79K ↗

Funds (13F)

39.6% held by 122 managers · as of Sep 30, 2026

ManagerValueChange
BlackRock, Inc.$25.79M+333.16K (+7.5%)
DEERFIELD MANAGEMENT COMPANY, L.P.$18.25M—
VANGUARD CAPITAL MANAGEMENT LLC$17.73M−211.25K (−6.1%)
JOSH ARNOLD INVESTMENT CONSULTANT, LLC$13.38M—
GEODE CAPITAL MANAGEMENT, LLC$10.32M+142.15K (+8.1%)

Congress

12 trades 12 sales · 0 purchases · 1 members, 12 months

MemberTypeAmount
Richard BlumenthalSep 23, 2026Partial sale$1K–$15K
Richard BlumenthalSep 23, 2026Partial sale$1K–$15K
Richard BlumenthalSep 22, 2026Partial sale$1K–$15K
Richard BlumenthalSep 22, 2026Partial sale$15K–$50K

Short interest

7.35% of float · 5.62 days to cover · Oct 15, 2026

Short position, last two years · 71% of its 2-year range

Source: FINRA

No headlines in the business press in the last 30 days.

Company data reported to the SEC on EDGAR (CIK 1799191).

Everything on STLN, in full

Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.

Start your free trial